Babaodan overcomes cisplatin resistance in cholangiocarcinoma via inhibiting YAP1

References

• Alam M, Alam S, Shamsi A, Adnan M, Elasbali AM, Al-Soud WA, Alreshidi M, Hawsawi YM, Tippana A, Pasupuleti VR, et al. 2022. Bax/Bcl-2 Cascade is regulated by the EGFR pathway: therapeutic targeting of non-small cell lung cancer. Front Oncol. 12:869672. doi: 10.3389/fonc.2022.869672.
   PubMed Web of Science ®Google Scholar
• Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, et al. 2020. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 17(9):557–588. doi: 10.1038/s41575-020-0310-z.
   PubMed Web of Science ®Google Scholar
• Bansal A, Simon MC. 2018. Glutathione metabolism in cancer progression and treatment resistance. J Cell Biol. 217(7):2291–2298. doi: 10.1083/jcb.201804161.
   PubMed Web of Science ®Google Scholar
• Chaouhan HS, Jha RR, Patel DK, Kar Chowdhuri D. 2021. CrVI-induced DNA damage is lessened by the modulation of hsp70 via increased GSH de novo synthesis in Drosophila melanogaster. J Biochem Mol Toxicol. 35(8):e22819. doi: 10.1002/jbt.22819.
   PubMed Web of Science ®Google Scholar
• Chen P, Liu XQ, Lin X, Gao LY, Zhang S, Huang X. 2021. Targeting YTHDF1 effectively re-sensitizes cisplatin-resistant colon cancer cells by modulating GLS-mediated glutamine metabolism. Mol Ther Oncolytics. 20:228–239. doi: 10.1016/j.omto.2021.01.001.
   PubMed Web of Science ®Google Scholar
• Chen Z, Lin T, Liao X, Li Z, Lin R, Qi X, Chen G, Sun L, Lin L. 2021. Network pharmacology based research into the effect and mechanism of Yinchenhao Decoction against cholangiocarcinoma. Chin Med. 16(1):13. doi: 10.1186/s13020-021-00423-4.
   PubMed Web of Science ®Google Scholar
• Ciamporcero E, Daga M, Pizzimenti S, Roetto A, Dianzani C, Compagnone A, Palmieri A, Ullio C, Cangemi L, Pili R, et al. 2018. Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer. Free Radic Biol Med. 115:447–457. doi: 10.1016/j.freeradbiomed.2017.12.005.
   PubMed Web of Science ®Google Scholar
• Delic M, Graf AB, Koellensperger G, Haberhauer-Troyer C, Hann S, Mattanovich D, Gasser B. 2014. Overexpression of the transcription factor Yap1 modifies intracellular redox conditions and enhances recombinant protein secretion. Microb Cell. 1(11):376–386. doi: 10.15698/mic2014.11.173.
   PubMedGoogle Scholar
• Dwyer BJ, Jarman EJ, Gogoi-Tiwari J, Ferreira-Gonzalez S, Boulter L, Guest RV, Kendall TJ, Kurian D, Kilpatrick AM, Robson AJ, et al. 2021. TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression. J Hepatol. 74(4):860–872. doi: 10.1016/j.jhep.2020.11.018.
   PubMed Web of Science ®Google Scholar
• Edwards DN, Ngwa VM, Wang S, Shiuan E, Brantley-Sieders DM, Kim LC, Reynolds AB, Chen J. 2017. The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ. Sci Signal. 10(508):eaan4667. doi: 10.1126/scisignal.aan4667.
   PubMed Web of Science ®Google Scholar
• Gao R, Kalathur RKR, Coto-Llerena M, Ercan C, Buechel D, Shuang S, Piscuoglio S, Dill MT, Camargo FD, Christofori G, et al. 2021. YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Mol Med. 13(12):e14351. doi: 10.15252/emmm.202114351.
   PubMed Web of Science ®Google Scholar
• Ge X, Huang S, Ren C, Zhao L. 2023. Taurocholic acid and glycocholic acid inhibit inflammation and activate farnesoid X receptor expression in LPS-stimulated zebrafish and macrophages. Molecules. 28(5):2005. doi: 10.3390/molecules28052005.
   PubMed Web of Science ®Google Scholar
• Ghosh S. 2019. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 88:102925. doi: 10.1016/j.bioorg.2019.102925.
   PubMed Web of Science ®Google Scholar
• Goldstein M, Kastan MB. 2015. The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu Rev Med. 66(1):129–143. doi: 10.1146/annurev-med-081313-121208.
   PubMedGoogle Scholar
• Guedj N. 2022. Pathology of cholangiocarcinomas. Curr Oncol. 30(1):370–380. doi: 10.3390/curroncol30010030.
   PubMed Web of Science ®Google Scholar
• He L, Yuan L, Yu W, Sun Y, Jiang D, Wang X, Feng X, Wang Z, Xu J, Yang R, et al. 2020. A regulation loop between YAP and NR4A1 balances cell proliferation and apoptosis. Cell Rep. 33(3):108284. doi: 10.1016/j.celrep.2020.108284.
   PubMed Web of Science ®Google Scholar
• Hu X, Deng J, Yu T, Chen S, Ge Y, Zhou Z, Guo Y, Ying H, Zhai Q, Chen Y, et al. 2019. ATF4 deficiency promotes intestinal inflammation in mice by reducing uptake of glutamine and expression of antimicrobial peptides. Gastroenterology. 156(4):1098–1111. doi: 10.1053/j.gastro.2018.11.033.
   PubMed Web of Science ®Google Scholar
• Huang D, Zhang X, Zhang C, Li H, Li D, Hu Y, Yang F, Qi Y. 2018. 2,4-Dichlorophenol induces DNA damage through ROS accumulation and GSH depletion in goldfish Carassius auratus. Environ Mol Mutagen. 59(9):798–804. doi: 10.1002/em.22209.
   PubMed Web of Science ®Google Scholar
• Jia Y, Zhang W, Liu H, Peng L, Yang Z, Lou J. 2012. Inhibition of glutathione synthesis reverses Krüppel-like factor 4-mediated cisplatin resistance. Cancer Chemother Pharmacol. 69(2):377–385. doi: 10.1007/s00280-011-1708-7.
   PubMed Web of Science ®Google Scholar
• Kennedy L, Sandhu JK, Harper ME, Cuperlovic-Culf M. 2020. Role of glutathione in cancer: from mechanisms to therapies. Biomolecules. 10(10):1429. doi: 10.3390/biom10101429.
   PubMed Web of Science ®Google Scholar
• Khan SA, Tavolari S, Brandi G. 2019. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 39 Suppl 1(S1):19–31. doi: 10.1111/liv.14095.
   PubMedGoogle Scholar
• Kleih M, Böpple K, Dong M, Gaißler A, Heine S, Olayioye MA, Aulitzky WE, Essmann F. 2019. Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells. Cell Death Dis. 10(11):851. doi: 10.1038/s41419-019-2081-4.
   PubMedGoogle Scholar
• Kobayashi M, Yonezawa A, Takasawa H, Nagao Y, Iguchi K, Endo S, Ikari A, Matsunaga T. 2022. Development of cisplatin resistance in breast cancer MCF7 cells by up-regulating aldo-keto reductase 1C3 expression, glutathione synthesis and proteasomal proteolysis. J Biochem. 171(1):97–108. doi: 10.1093/jb/mvab117.
   PubMed Web of Science ®Google Scholar
• Li Q, Zhan M, Chen W, Zhao B, Yang K, Yang J, Yi J, Huang Q, Mohan M, Hou Z, et al. 2016. Phenylethyl isothiocyanate reverses cisplatin resistance in biliary tract cancer cells via glutathionylation-dependent degradation of Mcl-1. Oncotarget. 7(9):10271–10282. doi: 10.18632/oncotarget.7171.
   PubMedGoogle Scholar
• Liu CW, Hua KT, Li KC, Kao HF, Hong RL, Ko JY, Hsiao M, Kuo ML, Tan CT. 2017. Histone methyltransferase G9a drives chemotherapy resistance by regulating the glutamate-cysteine ligase catalytic subunit in head and neck squamous cell carcinoma. Mol Cancer Ther. 16(7):1421–1434. doi: 10.1158/1535-7163.MCT-16-0567-T.
   PubMed Web of Science ®Google Scholar
• Liu J, Chen Y, Cao Z, Guan B, Peng J, Chen Y, Zhan Z, Sferra TJ, Sankararaman S, Lin J. 2020. Babao Dan inhibits the migration and invasion of gastric cancer cells by suppressing epithelial-mesenchymal transition through the TGF-β/Smad pathway. J Int Med Res. 48(6):300060520925598. doi: 10.1177/0300060520925598.
   PubMed Web of Science ®Google Scholar
• Liu Z, Peng Q, Li Y, Gao Y. 2018. Resveratrol enhances cisplatin-induced apoptosis in human hepatoma cells via glutamine metabolism inhibition. BMB Rep. 51(9):474–479. doi: 10.5483/BMBRep.2018.51.9.114.
   PubMed Web of Science ®Google Scholar
• Mohajan S, Jaiswal PK, Vatanmakarian M, Yousefi H, Sankaralingam S, Alahari SK, Koul S, Koul HK. 2021. Hippo pathway: regulation, deregulation and potential therapeutic targets in cancer. Cancer Lett. 507:112–123. doi: 10.1016/j.canlet.2021.03.006.
   PubMed Web of Science ®Google Scholar
• Owen JB, Butterfield DA. 2010. Measurement of oxidized/reduced glutathione ratio. Methods Mol Biol. 648:269–277. doi: 10.1007/978-1-60761-756-3_18.
   PubMedGoogle Scholar
• Prasopporn S, Suppramote O, Ponvilawan B, Jamyuang C, Chanthercrob J, Chaiboonchoe A, More-Krong P, Kongsri K, Suntiparpluacha M, Chanwat R, et al. 2022. Combining the SMAC mimetic LCL161 with gemcitabine plus cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma. Front Oncol. 12:1021632. doi: 10.3389/fonc.2022.1021632.
   PubMed Web of Science ®Google Scholar
• Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. 2018. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 15(2):95–111. doi: 10.1038/nrclinonc.2017.157.
   PubMed Web of Science ®Google Scholar
• Rodrigues PM, Olaizola P, Paiva NA, Olaizola I, Agirre-Lizaso A, Landa A, Bujanda L, Perugorria MJ, Banales JM. 2021. Pathogenesis of cholangiocarcinoma. Annu Rev Pathol. 16(1):433–463. doi: 10.1146/annurev-pathol-030220-020455.
   PubMedGoogle Scholar
• Rothkamm K, Barnard S, Moquet J, Ellender M, Rana Z, Burdak-Rothkamm S. 2015. DNA damage foci: meaning and significance. Environ Mol Mutagen. 56(6):491–504. doi: 10.1002/em.21944.
   PubMed Web of Science ®Google Scholar
• Sheng H, Li Y, Liu W, Wang Y, Wang S, Zhan Z, Lai Z, Guan B, Qiang S, Qian J, et al. 2022. Identification of bioactive ingredients from Babaodan using UPLC-QTOF-MS analysis combined with network pharmacology guided bioassays. J Chromatogr B Analyt Technol Biomed Life Sci. 1206:123356. doi: 10.1016/j.jchromb.2022.123356.
   PubMed Web of Science ®Google Scholar
• Sugiura K, Mishima T, Takano S, Yoshitomi H, Furukawa K, Takayashiki T, Kuboki S, Takada M, Miyazaki M, Ohtsuka M. 2019. The expression of Yes-associated protein (YAP) maintains putative cancer stemness and is associated with poor prognosis in intrahepatic cholangiocarcinoma. Am J Pathol. 189(9):1863–1877. doi: 10.1016/j.ajpath.2019.05.014.
   PubMed Web of Science ®Google Scholar
• Teixeira E, Silva C, Martel F. 2021. The role of the glutamine transporter ASCT2 in antineoplastic therapy. Cancer Chemother Pharmacol. 87(4):447–464. doi: 10.1007/s00280-020-04218-6.
   PubMed Web of Science ®Google Scholar
• Tong Y, Guo D, Lin SH, Liang J, Yang D, Ma C, Shao F, Li M, Yu Q, Jiang Y, et al. 2021. SUCLA2-coupled regulation of GLS succinylation and activity counteracts oxidative stress in tumor cells. Mol Cell. 81(11):2303–2316.e2308. doi: 10.1016/j.molcel.2021.04.002.
   PubMed Web of Science ®Google Scholar
• Tusskorn O, Prawan A, Senggunprai L, Kukongviriyapan U, Kukongviriyapan V. 2013. Phenethyl isothiocyanate induces apoptosis of cholangiocarcinoma cells through interruption of glutathione and mitochondrial pathway. Naunyn Schmiedebergs Arch Pharmacol. 386(11):1009–1016. doi: 10.1007/s00210-013-0906-8.
   PubMed Web of Science ®Google Scholar
• Wang Q, Liu Z, Du K, Liang M, Zhu X, Yu Z, Chen R, Qin L, Li Y, Zheng Y. 2019. Babaodan inhibits cell growth by inducing autophagy through the PI3K/AKT/mTOR pathway and enhances antitumor effects of cisplatin in NSCLC cells. Am J Transl Res. 11:5272–5283.
   PubMed Web of Science ®Google Scholar
• Wilkins HM, Marquardt K, Lash LH, Linseman DA. 2012. Bcl-2 is a novel interacting partner for the 2-oxoglutarate carrier and a key regulator of mitochondrial glutathione. Free Radic Biol Med. 52(2):410–419. doi: 10.1016/j.freeradbiomed.2011.10.495.
   PubMed Web of Science ®Google Scholar
• Xiao X, Wang K, Zong Q, Tu Y, Dong Y, Yuan Y. 2021. Polyprodrug with glutathione depletion and cascade drug activation for multi-drug resistance reversal. Biomaterials. 270:120649. doi: 10.1016/j.biomaterials.2020.120649.
   PubMed Web of Science ®Google Scholar
• Xu Y, Ye H. 2022. Progress in understanding the mechanisms of resistance to BCL-2 inhibitors. Exp Hematol Oncol. 11(1):31. doi: 10.1186/s40164-022-00283-0.
   PubMed Web of Science ®Google Scholar
• Yang L, He K, Yao S, Zhang Y, Shen J. 2021. Sevoflurane inhibits neuroblastoma cell proliferation and invasion and induces apoptosis by miR-144-3p/YAP1 axis. Basic Clin Pharmacol Toxicol. 129(4):297–307. doi: 10.1111/bcpt.13629.
   PubMed Web of Science ®Google Scholar
• Yao W, Guo P, Mu Q, Wang Y. 2021. Exosome-derived circ-PVT1 contributes to cisplatin resistance by regulating autophagy, invasion, and apoptosis via miR-30a-5p/YAP1 axis in gastric cancer cells. Cancer Biother Radiopharm. 36(4):347–359. doi: 10.1089/cbr.2020.3578.
   PubMed Web of Science ®Google Scholar
• Yoo HC, Park SJ, Nam M, Kang J, Kim K, Yeo JH, Kim JK, Heo Y, Lee HS, Lee MY, et al. 2020. A variant of SLC1A5 is a mitochondrial glutamine transporter for metabolic reprogramming in cancer cells. Cell Metab. 31(2):267–283.e212. doi: 10.1016/j.cmet.2019.11.020.
   PubMed Web of Science ®Google Scholar
• Yoon H, Min JK, Lee JW, Kim DG, Hong HJ. 2011. Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2. Biochem Biophys Res Commun. 405(3):333–337. doi: 10.1016/j.bbrc.2010.11.130.
   PubMed Web of Science ®Google Scholar
• Zhang J, Tong Y, Lu X, Dong F, Ma X, Yin S, He Y, Liu Y, Liu Q, Fan D. 2022. A derivant of ginsenoside CK and its inhibitory effect on hepatocellular carcinoma. Life Sci. 304:120698. doi: 10.1016/j.lfs.2022.120698.
   PubMed Web of Science ®Google Scholar
• Zhang X, Heng Y, Kooistra SM, van Weering HRJ, Brummer ML, Gerrits E, Wesseling EM, Brouwer N, Nijboer TW, Dubbelaar ML, et al. 2021. Intrinsic DNA damage repair deficiency results in progressive microglia loss and replacement. Glia. 69(3):729–745. doi: 10.1002/glia.23925.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu H, Cui G, Liang B, Chen X, Ko S, Affo S, Song X, Liao Y, Feng J, et al. 2022. β-Catenin sustains and is required for YES-associated protein oncogenic activity in cholangiocarcinoma. Gastroenterology. 163(2):481–494. doi: 10.1053/j.gastro.2022.04.028.
   PubMed Web of Science ®Google Scholar
• Zhao J, Lan W, Peng J, Guan B, Liu J, Zhang M, Zhan Z, Lin J. 2021. Babao Dan reverses multiple-drug resistance in gastric cancer cells via triggering apoptosis and autophagy and inhibiting PI3K/AKT/mTOR signaling. Evid Based Complement Alternat Med. 2021:5631942. doi: 10.1155/2021/5631942.
   PubMed Web of Science ®Google Scholar
• Zheng Q, Zhang B, Li C, Zhang X. 2022. Overcome drug resistance in cholangiocarcinoma: new insight into mechanisms and refining the preclinical experiment models. Front Oncol. 12:850732. doi: 10.3389/fonc.2022.850732.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Lin Y, Zhu M, Chen T, Cheng Z, Lin Y, Huang JCM. 2022. Simultaneous determination of 15 bile acids in Babaodan by UPLC-MS/MS. J Pharm Anal. 42:2186–2194.
   Google Scholar
• Zong C, Kimura Y, Kinoshita K, Takasu S, Zhang X, Sakurai T, Sekido Y, Ichihara S, Endo G, Ichihara G. 2019. Exposure to 1,2-dichloropropane upregulates the expression of activation-induced cytidine deaminase (AID) in human cholangiocytes co-cultured with macrophages. Toxicol Sci. 168(1):137–148. doi: 10.1093/toxsci/kfy280.
   PubMed Web of Science ®Google Scholar